La bourse ferme dans 4 h 32 min
  • CAC 40

    5 597,21
    +30,42 (+0,55 %)
     
  • Euro Stoxx 50

    3 526,16
    +15,22 (+0,43 %)
     
  • Dow Jones

    29 872,47
    -173,77 (-0,58 %)
     
  • EUR/USD

    1,1929
    +0,0016 (+0,13 %)
     
  • Gold future

    1 809,70
    -1,50 (-0,08 %)
     
  • BTC-EUR

    14 113,23
    -299,32 (-2,08 %)
     
  • CMC Crypto 200

    328,98
    -41,54 (-11,21 %)
     
  • Pétrole WTI

    45,42
    -0,29 (-0,63 %)
     
  • DAX

    13 324,59
    +38,02 (+0,29 %)
     
  • FTSE 100

    6 339,90
    -23,03 (-0,36 %)
     
  • Nasdaq

    12 094,40
    +57,62 (+0,48 %)
     
  • S&P 500

    3 629,65
    -5,76 (-0,16 %)
     
  • Nikkei 225

    26 644,71
    +107,40 (+0,40 %)
     
  • HANG SENG

    26 894,68
    +75,23 (+0,28 %)
     
  • GBP/USD

    1,3319
    -0,0038 (-0,28 %)
     

Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19

Brian Orelli, PhD, The Motley Fool
·4 min de lecture

Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete. Brian Orelli: We talked about a lot of different products. Henry Ji: Brian, our company has a lot of expertise, especially the antibodies space.